Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis

Huiyan Ma; Giske Ursin; Xinxin Xu; Eunjung Lee; Kayo Togawa; Kathleen E. Malone; Polly A. Marchbanks; Jill A. McDonald; Michael S. Simon; Suzanne G. Folger; Yani Lu; Jane Sullivan-Halley; Dennis M. Deapen; Michael F. Press; Leslie Bernstein

doi:10.1186/s13058-017-0931-5

Table 4 Adjusted^a odds ratio (OR) and 95% confidence interval (CI) for joint effect of BMI at age 18 years and recent BMI in relation to risk of breast cancer overall and luminal-like subtype in premenopausal women

From: Body mass index at age 18 years and recent body mass index in relation to risk of breast cancer overall and ER/PR/HER2-defined subtypes in white women and African-American women: a pooled analysis

BMI at age 18 years, kg/m²	Recent BMI, kg/m²	Controls	All cases		luminal-like (ER+ and/or PR+)
BMI at age 18 years, kg/m²	Recent BMI, kg/m²	Number	Number	OR (95% CI)	Number	OR (95% CI)
Overall
< 20.0	< 25.0	472	952	Referent	540	Referent
< 20.0	25.0–29.9	96	184	0.93 (0.70–1.24)	92	0.79 (0.56–1.13)
< 20.0	≥ 30.0	20	51	1.21 (0.69–2.13)	24	0.99 (0.50–1.96)
20.0–24.9	< 25.0	265	555	1.03 (0.85–1.25)	311	1.00 (0.79–1.26)
20.0–24.9	25.0–29.9	171	302	0.87 (0.69–1.10)	151	0.77 (0.58–1.02)
20.0–24.9	≥ 30.0	107	210	0.86 (0.65–1.13)	115	0.84 (0.60–1.17)
≥ 25.0	< 25.0	21	38	0.89 (0.50–1.58)	17	0.65 (0.32–1.35)
≥ 25.0	25.0–29.9	32	47	0.75 (0.46–1.22)	26	0.79 (0.43–1.44)
≥ 25.0	≥ 30.0	73	88	0.54 (0.38–0.78)	40	0.46 (0.29–0.73)
Restricted to studies in which cases’ ER/PR/HER2 status determined in a central laboratory
< 20.0	< 25.0	342	448	Referent	183	Referent
< 20.0	25.0–29.9	70	86	0.94 (0.66–1.35)	31	0.79 (0.49–1.29)
<20.0	≥ 30.0	16	21	1.03 (0.52–2.05)	6	0.67 (0.25–1.83)
20.0–24.9	< 25.0	186	253	1.05 (0.83–1.34)	103	1.03 (0.75–1.42)
20.0–24.9	25.0–29.9	132	148	0.86 (0.65–1.15)	55	0.75 (0.51–1.11)
20.0–24.9	≥ 30.0	81	89	0.78 (0.55–1.11)	37	0.79 (0.50–1.25)
≥ 25.0	< 25.0	15	23	1.09 (0.55–2.16)	8	0.83 (0.33–2.08)
≥ 25.0	25.0–29.9	27	23	0.68 (0.38–1.22)	11	0.76 (0.36–1.62)
≥ 25.0	≥ 30.0	58	41	0.52 (0.33–0.81)	15	0.46 (0.25–0.86)
Restricted to invasive cases
< 20.0	< 25.0	472	849	Referent	485	Referent
< 20.0	25.0–29.9	96	169	0.94 (0.70–1.26)	86	0.83 (0.58–1.20)
< 20.0	≥ 30.0	20	51	1.35 (0.77–2.38)	24	1.13 (0.56–2.28)
20.0–24.9	< 25.0	265	506	1.04 (0.85–1.27)	287	1.03 (0.81–1.32)
20.0–24.9	25.0–29.9	171	286	0.92 (0.72–1.17)	143	0.84 (0.62–1.13)
20.0–24.9	≥ 30.0	107	201	0.89 (0.67–1.18)	114	0.94 (0.67–1.34)
≥ 25.0	< 25.0	21	33	0.87 (0.48–1.59)	14	0.58 (0.27–1.26)
≥ 25.0	25.0–29.9	32	44	0.80 (0.48–1.32)	25	0.89 (0.48–1.66)
≥ 25.0	≥ 30.0	73	85	0.58 (0.40–0.84)	40	0.53 (0.33–0.85)

Abbreviations: ER estrogen receptor, PR progesterone receptor, HER2 human epidermal growth factor receptor-2, BMI body mass index
^aORs obtained from multivariable polychotomous unconditional logistic regression models with adjustment for source study, study site, race, education, reference age, first-degree breast cancer family history, age at menarche, number of completed pregnancies, lifetime recreational physical activity, alcohol intake, cigarette smoking status, and oral contraceptive use

Back to article page